See today's BioWorld Asia
To read the full story, subscribe or sign in.

Alexion seeks Japanese nod for asfotase alfa in ultra-rare HPP

Oct. 22, 2014
By Catherine Makino
TOKYO – Alexion Pharmaceuticals Inc. is looking for Japanese approval for its drug, asfotase alfa, to treat patients suffering from hypophosphatasia (HPP), an ultra-rare genetic bone disorder.
BioWorld Asia